AltMountain

The B Group, Inc.

Dallas, TX · CRD 310357
Hedge fund managerExempt reporting

The B Group, Inc. is an exempt reporting adviser based in Dallas, TX that reports managing 1 hedge fund on Form ADV. Its private funds, of all types, hold $115.6 million in gross assets. Its disclosed U.S. stock holdings returned an estimated -10.9% 2026 YTD through Jun 30 (S&P 500: +9.5%), based on 13F filings. Over a longer period they returned an estimated +144.3% from Q1 2025 to Q2 2026, compared with +27.4% for the S&P 500, based on 13F filings.

Regulatory assets under management
—Form ADV Item 5.F
Gross assets of private funds
$115.6 millionAll private fund types, Form ADV
Hedge funds managed
11 private funds in total
Employees
—Form ADV Item 5.A
Registration
Exempt reporting adviserCRD 310357
Latest Form ADV
03/03/2026Disciplinary disclosures: none reported

Estimated 13F portfolio performance

Estimated by AltMountain, derived from the firm’s public Form 13F filings. Not reported by the firm and not the return of any fund.

Estimated from 13F · 2026 YTD-10.9%Through Q2 2026 · S&P 500 +9.5%
Estimated from 13F · 6 quarters+144.3%Q1 2025 – Q2 2026
S&P 500+27.4%Same quarters, price only
13F holdings$176.2 million18 positions, 2026-06-30
$95$185$274Q1 2025Q3 2025Q1 202613F est. $244S&P 500 $127
QuarterEst. 13F returnS&P 500
Q2 2026+18.3%+14.8%
Q1 2026-24.6%-4.6%
Q4 2025+20.5%+2.4%
Q3 2025+1.2%+7.8%
Q2 2025+7.8%+10.4%
Q1 2025+108.5%-4.5%

Estimate of the firm's disclosed long U.S. stock portfolio from its quarterly 13F filings, holding each quarter-end portfolio to the next quarter-end at prices implied by all 13F filers. It is a price return before dividends and fees, ignores shorts, options, bonds, cash and trading within the quarter, and is not the return of any fund. Disclosures

Manager of this firm? Report your fund’s actual net return, or email hello@altmountain.com to correct or remove this estimate. Removal requests from the firm are honored.

13F holdings as of Sep 30, 2026

All 19 share positions ($162,133,739) reported by B Group, Inc. on Form 13F for the quarter ended Sep 30, 2026, filed Nov 16, 2026. Shown as filed with the SEC. Original filing on SEC.gov ↗ The estimated return above runs through Jun 30, 2026; it is updated when the SEC publishes its complete data for the quarter.

Share of the reported 13F portfolio, ten largest positions

  • Adma Biologics Inc20.18%
  • Faeth Therapeutics Inc11.19%
  • Palisade Bio Inc9.50%
  • NRX Pharmaceuticals Inc7.70%
  • Zai Lab LTD7.32%
  • Praxis Precision Medicines I5.97%
  • Sight Sciences Inc5.60%
  • Taysha Gene Therapies Inc5.41%
  • Iovance Biotherapeutics Inc3.88%
  • Structure Therapeutics Inc3.47%
StockValue% of 13F portfolioSharesShares vs prior quarter
Adma Biologics Inc$32,723,29620.18%3,262,542Unchanged
Faeth Therapeutics Inc$18,146,42611.19%610,169Unchanged
Palisade Bio Inc$15,409,2859.50%11,414,285Unchanged
NRX Pharmaceuticals Inc$12,489,4247.70%4,277,200+4.53%
Zai Lab LTD$11,870,0167.32%450,646Unchanged
Praxis Precision Medicines I$9,679,6125.97%33,237Unchanged
Sight Sciences Inc$9,079,2005.60%970,000Unchanged
Taysha Gene Therapies Inc$8,768,7085.41%1,800,556Unchanged
Iovance Biotherapeutics Inc$6,298,5003.88%425,000+13.33%
Structure Therapeutics Inc$5,628,6003.47%180,000-14.29%
Spyre Therapeutics Inc$5,564,3753.43%62,500-10.71%
Cellectis S A$4,955,0673.06%3,281,501Unchanged
Aura Biosciences Inc$4,799,4462.96%764,243Unchanged
Bright Minds Biosciences Inc$4,732,9002.92%95,000+40.74%
Oruka Therapeutics Inc$4,580,9502.83%55,000-26.67%
Assembly Biosciences Inc$4,127,3342.55%175,706Unchanged
Ultragenyx Pharmaceutical In$2,029,0501.25%135,000Unchanged
Foghorn Therapeutics Inc$714,0000.44%200,000Unchanged
Q32 Bio Inc$537,5500.33%65,000New

Changes since Jun 30, 2026

Comparing the share counts in the two quarter-end filings: 1 new position, 0 sold out, 3 increased, 3 reduced and 12 unchanged.

Number of positions (a count, not dollars)

  • New positions1
  • Increased3
  • Unchanged12
  • Reduced3
  • Sold out0

New positions

StockValueShares
Q32 Bio Inc$537,55065,000

Largest increases

StockChange in sharesChangeValue nowShares now
Bright Minds Biosciences Inc+27,500+40.74%$4,732,90095,000
Iovance Biotherapeutics Inc+50,000+13.33%$6,298,500425,000
NRX Pharmaceuticals Inc+185,433+4.53%$12,489,4244,277,200

Largest reductions

StockChange in sharesChangeValue nowShares now
Oruka Therapeutics Inc-20,000-26.67%$4,580,95055,000
Structure Therapeutics Inc-30,000-14.29%$5,628,600180,000
Spyre Therapeutics Inc-7,500-10.71%$5,564,37562,500

Each list shows up to 20 positions, largest first by dollar amount. Changes compare two quarter-end snapshots, with the earlier share count adjusted for stock splits AltMountain detected. They do not show when, or at what price, anything was bought or sold.

From public Form 13F filings, not verified. Form 13F is filed up to 45 days after the quarter ends, so positions may have changed. It lists only certain long positions in U.S.-listed stocks and exchange-traded funds; options are not shown here, and short positions, most bonds, cash, non-U.S. securities and private investments are not reported at all, so a holding may be one side of a hedge. A filing covers the manager as a whole, not any single fund, and filings contain errors. This is not investment advice or a recommendation to buy or sell any security. Disclosures

Large ownership stakes (Schedule 13D and 13G)

CompanyFilingPercent of classSharesFiledSource
Retension Pharmaceuticals, Inc.13G10%833,333Oct 16, 2026SEC.gov ↗

A firm files Schedule 13G (passive) or 13D (it may seek to influence the company) when it beneficially owns more than 5% of a class of a public company's shares. Each row is the firm's latest such filing for that company since Oct 16, 2026, exactly as filed, and counts shares held across the firm and its affiliates, not by any single fund. An amendment can report a stake that has fallen below 5%. Holdings may have changed since the filing date. Not verified by AltMountain. Source: U.S. Securities and Exchange Commission, EDGAR.

Private funds reported on Form ADV (1)

As reported in the adviser's Form ADV filed Apr 22, 2024. Funds also listed from Form D are shown above.

From SEC filings. Firm data comes from the SEC's Form ADV data as of Oct 2, 2026; performance estimates come from Form 13F. AltMountain has not verified this information, and it is not an offer, solicitation or recommendation. Full disclosures⁠​​‌‌‌‌‌‌‌​‌‌‌‌‌‌‌‌​‌⁠